Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01974427
Other study ID # 140002
Secondary ID 14-N-0002
Status Completed
Phase
First received
Last updated
Start date October 26, 2013
Est. completion date June 20, 2018

Study information

Verified date May 29, 2019
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Objective:

The goal of this protocol is to improve understanding scale-free brain activity and conscious vs. unconscious processing by performing small behavioral, electrophysiological, neuroimaging and brain stimulation pilot substudies. This research is expected to help develop techniques and hypotheses for future research on these topics.

We will conduct:

- Pilot Substudy: Pilot substudies are exploratory in nature, in order to develop enough information to generate a hypothesis. The criterion for transition to a new full protocol will be acquisition of sufficient information to generate a power analysis. There are no enrollment limitations for pilot substudies.

- Hypothesis-Testing Substudy is defined as a study with a specific hypothesis to be tested that can be completed with a few healthy volunteers or patients. Hypothesis-testing substudies will undergo statistical and PIRC reviews after 6 subjects (if there is one group) or after 12 (6 per arm) if two groups are studied before additional subjects are recruited. In the event of subject dropout or unsuccessful recording, replacement will be recruited. Together, the P.I. and PIRC will decide whether to continue the hypothesis substudy with more subjects without an amendment or whether an amendment or new protocol would be necessary. A memo requesting a review of hypothesis-testing substudies for possible additional enrollment will be sent to PIRC and the statistical reviewer. The memo will be forwarded to the CNS IRB.

- Technical development of new experimental paradigms and data analysis methods.

This protocol includes only non-invasive techniques with minimal risk (MRI, EEG, MEG, EMG, tDCS).

Study Population:

We plan to recruit up to 120 healthy volunteers aged 18-65.

Design:

We will design small projects that are pertinent to the theme of scale-free brain activity and conscious/unconscious processing. We will investigate healthy volunteers in the resting state or while they perform simple motor or sensory tasks. If a hypothesis testing substudy leads to results of interest and if a larger population is necessary to reach statistical significance, a separate protocol will be submitted with a priori hypotheses, specific study design and power analysis adapted from the pilot or exploratory substudies performed in the present protocol.

In the substudies, brain activity of healthy human volunteers will be monitored by functional magnetic resonance imaging (fMRI), magnetoencephalography (MEG), electroencephalography (EEG), or simultaneous MEG-EEG. Anatomical MRI will be collected in some subjects to allow better localization of brain dynamics. Because transcranial direct-current stimulation (tDCS) is ideally suited to modulate the slow component of scale-free brain activity, we will also investigate the effect of tDCS on brain activity and/or behavioral performance in cognitive tasks. tDCS will be administered sequentially, but not simultaneously, with brain-activity monitoring by fMRI/MEG/EEG. Most experiments will be conducted in conjunction with cognitive tasks. In some experiments, we will study resting-state brain function, during which spontaneous brain activity is collected without a specific externally administered task.

Outcome Measures:

MRI: to analyze measures such as the anatomical structures of the brain (using structural MRI); amplitude of the blood-oxygenation-level-dependent (BOLD) signal (using fMRI); cerebral blood flow [using arterial spin labeling (ASL)] and different neurotransmitter levels in brain regions of interest [using magnetic resonance spectroscopy (MRS)].

EEG and MEG: to quantify measures such as power spectrum, event- or task-related potentials, synchronization/desynchronization, and coherence between sensors or sources located close to the brain areas of interest.

tDCS: to analyze changes in behavioral measures and/or fMRI/EEG/MEG activity caused by tDCS.

Behavioral measures: to quantify measures such as hit rate, reaction times, electromyography (EMG) patterns.

We may measure autonomic data during the course of the experiment (such as heart rate, respiration, end-tidal CO2, skin conductance), which will be correlated with the outcome measures.


Description:

Objective:

The goal of this protocol is to improve understanding scale-free brain activity and conscious vs. unconscious processing by performing small behavioral, electrophysiological, neuroimaging and brain stimulation pilot substudies. This research is expected to help develop techniques and hypotheses for future research on these topics.

We will conduct:

- Pilot Substudy: Pilot substudies are exploratory in nature, in order to develop enough information to generate a hypothesis. The criterion for transition to a new full protocol will be acquisition of sufficient information to generate a power analysis. There are no enrollment limitations for pilot substudies.

- Hypothesis-Testing Substudy is defined as a study with a specific hypothesis to be tested that can be completed with a few healthy volunteers or patients. Hypothesis-testing substudies will undergo statistical and PIRC reviews after 6 subjects (if there is one group) or after 12 (6 per arm) if two groups are studied before additional subjects are recruited. In the event of subject dropout or unsuccessful recording, replacement will be recruited. Together, the P.I. and PIRC will decide whether to continue the hypothesis substudy with more subjects without an amendment or whether an amendment or new protocol would be necessary. A memo requesting a review of hypothesis-testing substudies for possible additional enrollment will be sent to PIRC and the statistical reviewer. The memo will be forwarded to the CNS IRB.

- Technical development of new experimental paradigms and data analysis methods.

This protocol includes only non-invasive techniques with minimal risk (MRI, EEG, MEG, EMG, tDCS).

Study Population:

We plan to recruit up to 200 healthy volunteers aged 18-65.

Design:

We will design small projects that are pertinent to the theme of scale-free brain activity and conscious/unconscious processing. We will investigate healthy volunteers in the resting state or while they perform simple motor or sensory tasks. If a hypothesis testing substudy leads to results of interest and if a larger population is necessary to reach statistical significance, a separate protocol will be submitted with a priori hypotheses, specific study design and power analysis adapted from the pilot or exploratory substudies performed in the present protocol.

In the substudies, brain activity of healthy human volunteers will be monitored by functional magnetic resonance imaging (fMRI), magnetoencephalography (MEG), electroencephalography (EEG), or simultaneous MEG-EEG. Anatomical MRI will be collected in some subjects to allow better localization of brain dynamics. Because transcranial direct-current stimulation (tDCS) is ideally suited to modulate the slow component of scale-free brain activity, we will also investigate the effect of tDCS on brain activity and/or behavioral performance in cognitive tasks. tDCS will be administered sequentially, but not simultaneously, with brain-activity monitoring by fMRI/MEG/EEG. Most experiments will be conducted in conjunction with cognitive tasks. In some experiments, we will study resting-state brain function, during which spontaneous brain activity is collected without a specific externally administered task.

Outcome Measures:

MRI: to analyze measures such as the anatomical structures of the brain (using structural MRI); amplitude of the blood-oxygenation-level-dependent (BOLD) signal (using fMRI); cerebral blood flow [using arterial spin labeling (ASL)] and different neurotransmitter levels in brain regions of interest [using magnetic resonance spectroscopy (MRS)].

EEG and MEG: to quantify measures such as power spectrum, event- or task-related potentials, synchronization/desynchronization, and coherence between sensors or sources located close to the brain areas of interest.

tDCS: to analyze changes in behavioral measures and/or fMRI/EEG/MEG activity caused by tDCS.

Behavioral measures: to quantify measures such as hit rate, reaction times, electromyography (EMG) patterns.

We may measure autonomic data during the course of the experiment (such as heart rate, respiration, end-tidal CO2, skin conductance), which will be correlated with the outcome measures.


Recruitment information / eligibility

Status Completed
Enrollment 154
Est. completion date June 20, 2018
Est. primary completion date June 20, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility - INCLUSION CRITERIA:

A subject can be included if he/she:

is in good general health;

is between 18 and 65 years old;

is capable of understanding the procedures and requirements of this study;

is willing and able to provide his/her own informed consent.

EXCLUSION CRITERIA:

A subject will be excluded if he/she:

has a contraindication to MR scanning such as the following: pregnancy, aneurysm clip; implanted neural stimulator; implanted cardiac pacemaker or auto-defibrillator; cochlear implant; ocular foreign body (e.g. metal shavings); insulin pump as per the NMR Safety Screening Form.

underwent brain surgery, who have a central nervous system illness, neurological lesion, a psychiatric history or recurrent migraines that require medication will also be excluded from this study: Healthy volunteer form.

has uncontrolled medical problems, such as diabetes mellitus, hypertension, pulmonary or airway disease, heart failure, coronary artery disease.

has metal in the cranial cavity and/or holes in the skull made by trauma or surgery.

cannot lie comfortably flat on their back for up to 180 minutes in the MRI scanner

has claustrophobia

Subjects may participate in this study, but will not be allowed to have a 7T MRI scan if they have metallic dental crowns or a bridge.

Subjects may participate in the study, but will not have tDCS if they have broken skin or a wound in the area where electrodes will be placed.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

References & Publications (3)

He BJ, Zempel JM, Snyder AZ, Raichle ME. The temporal structures and functional significance of scale-free brain activity. Neuron. 2010 May 13;66(3):353-69. doi: 10.1016/j.neuron.2010.04.020. — View Citation

He BJ. Scale-free properties of the functional magnetic resonance imaging signal during rest and task. J Neurosci. 2011 Sep 28;31(39):13786-95. doi: 10.1523/JNEUROSCI.2111-11.2011. — View Citation

Ray S, Maunsell JH. Different origins of gamma rhythm and high-gamma activity in macaque visual cortex. PLoS Biol. 2011 Apr;9(4):e1000610. doi: 10.1371/journal.pbio.1000610. Epub 2011 Apr 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Behavioral measures, brain activity recorded by MRI, EEG, MEG, as well as changes in the above measures induced by tDCS 10 years
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1